BioCryst Net Tangible Assets from 2010 to 2026
| BCRX Stock | USD 7.26 0.31 4.46% |
Net Tangible Assets | First Reported 2011-06-30 | Previous Quarter 192.1 M | Current Value 143.2 M | Quarterly Volatility 92.5 M |
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 979.9 K, Interest Expense of 119 M or Selling General Administrative of 304.9 M, as well as many indicators such as Price To Sales Ratio of 3.77, Dividend Yield of 0.0 or Days Sales Outstanding of 69.96. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
BioCryst | Net Tangible Assets | Build AI portfolio with BioCryst Stock |
The evolution of Net Tangible Assets for BioCryst Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BioCryst Pharmaceuticals compares to historical norms and industry peers.
Latest BioCryst Pharmaceuticals' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of BioCryst Pharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. BioCryst Pharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
BioCryst Net Tangible Assets Regression Statistics
| Arithmetic Mean | (57,711,690) | |
| Coefficient Of Variation | (275.44) | |
| Mean Deviation | 141,362,658 | |
| Median | 18,806,000 | |
| Standard Deviation | 158,961,701 | |
| Sample Variance | 25268.8T | |
| Range | 403.9M | |
| R-Value | (0.73) | |
| Mean Square Error | 12690.3T | |
| R-Squared | 0.53 | |
| Significance | 0.0009 | |
| Slope | (22,899,345) | |
| Total Sum of Squares | 404301.2T |
BioCryst Net Tangible Assets History
About BioCryst Pharmaceuticals Financial Statements
BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | -265.1 M | -251.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.